Latest News for: Daiichi Sankyo
Edit
Enhertu Supplemental New Drug Application Submitted in Japan for Patients with HER2 Expressing Advanced or Recurrent Uterine Carcinosarcoma (Daiichi Sankyo Co Ltd)
Public Technologies 12 Nov 2026
). The text version of this document is not available ... Daiichi Sankyo Co.
Edit
The Daily Record - Dunn
09 Nov 2026
iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted ...
The Daily Record - Dunn
09 Nov 2026
— Collaboration’s objective is to evaluate the potential of a cancer therapeutic by using iDEL’s unique shuttle ....
Edit
Enid News & Eagle
30 Oct 2026
Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
Enid News & Eagle
30 Oct 2026
Edit
Enhertu Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer (Daiichi Sankyo Co Ltd)
Public Technologies 27 Oct 2026
). The text version of this document is not available ... Daiichi Sankyo Co.
Edit
Times Argus
22 Oct 2026
Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO
Times Argus
22 Oct 2026
Edit
Enhertu Approved in China as First and Only Tumor Agnostic HER2 Directed Medicine and Antibody Drug Conjugate for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors (Daiichi Sankyo Co Ltd)
Public Technologies 22 Oct 2026
). The text version of this document is not available ... Daiichi Sankyo Co.
Edit
Datroway Approved in China as First and Only TROP2 Directed Antibody Drug Conjugate with Overall Survival Benefit for Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (Daiichi Sankyo Co Ltd)
Public Technologies 08 Oct 2026
). The text version of this document is not available ... Daiichi Sankyo Co.
Edit
Enhertu Approved in China as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer (Daiichi Sankyo Co Ltd)
Public Technologies 08 Oct 2026
Designed using the proprietary DXd ADC Technology of Daiichi Sankyo, Enhertu is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca's ADC scientific platform.
Edit
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types (Daiichi Sankyo Co Ltd)
Public Technologies 02 Oct 2026
) Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple ...
Edit
The Eagle-Tribune
02 Oct 2026
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® ...
The Eagle-Tribune
02 Oct 2026
Edit
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
GDN Online 02 Oct 2026
Edit
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combo
Sowetan Live 02 Oct 2026
Edit
Daiichi Sankyo Co., Ltd. Bond Rating Assigned AA (R&I - Rating and Investment Information Inc)
Public Technologies 02 Oct 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer ... (noodl.
Edit
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in ...
Business Wire 02 Oct 2026- 1
- 2
- Next page »